Wyoming MPJE (Pharmacy Jurisprudence) Practice Exam

C5 medications have a different regulatory status compared to other controlled substances. One key difference is that C5 medications are required to be reported to the Prescription Drug Monitoring Program (PDMP). This is crucial for monitoring the dispensing and prescribing of these medications to help prevent misuse, abuse, and diversion. The other options (B, C, D) do not accurately characterize C5 medications and do not align with their specific regulatory requirements.